What Is Tirzepatide?

Tirzepatide is a dual GIP and GLP-1 receptor agonist — a novel mechanism that distinguishes it from earlier GLP-1 drugs like semaglutide. By targeting both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor simultaneously, tirzepatide has shown strong efficacy in clinical trials for both blood sugar regulation and weight management.

It was developed by Eli Lilly and approved under the brand name Mounjaro for type 2 diabetes management, and subsequently as Zepbound for chronic weight management in adults with obesity or weight-related conditions. Like semaglutide, it is administered by subcutaneous injection once weekly.

Clinical trial data for tirzepatide has shown substantial weight loss outcomes, with some participants achieving reductions that exceed those seen in semaglutide trials. However, direct head-to-head comparison between the two drugs in large randomised controlled trials is limited, and individual responses vary significantly.

Clinics offering tirzepatide should provide a full medical assessment before prescribing, including a review of cardiovascular history, metabolic markers, and any contraindications. Side effects are broadly similar to other GLP-1 class drugs and include gastrointestinal symptoms particularly during dose escalation.

When comparing clinics offering tirzepatide, look for transparent prescriber credentials, a structured intake process, and clear follow-up protocols. Be cautious of providers offering rapid or assessment-free access.

This page is informational only. Peptide Clinic Finder does not prescribe or sell tirzepatide. Use this directory to compare clinic listings and contact providers directly.